Form 8-K - Current report:
SEC Accession No. 0001104659-23-008993
Filing Date
2023-02-01
Accepted
2023-02-01 08:18:32
Documents
13
Period of Report
2023-02-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm235110d1_8k.htm   iXBRL 8-K 29522
2 EXHIBIT 99.1 tm235110d1_ex99-1.htm EX-99.1 10269
  Complete submission text file 0001104659-23-008993.txt   216720

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20230201.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20230201_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20230201_pre.xml EX-101.PRE 22593
7 EXTRACTED XBRL INSTANCE DOCUMENT tm235110d1_8k_htm.xml XML 3483
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 23574806
SIC: 2834 Pharmaceutical Preparations